Introduction to MedDRA Coding in Drug Safety & Pharmacovigilance Process for Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Establishment of Pharmacovigilance ProgrammeNipun Gupta
1. Pharmacovigilance
2. Pathway of PvPI
3. Establishment of PV Programme
in Hospital
4. Establishment of PV Programme
in Industry
5. Contract Research Organization
6. Establishment a National Programme
Establishment of Pharmacovigilance ProgrammeNipun Gupta
1. Pharmacovigilance
2. Pathway of PvPI
3. Establishment of PV Programme
in Hospital
4. Establishment of PV Programme
in Industry
5. Contract Research Organization
6. Establishment a National Programme
Organization and objectives of ICH, expedited reporting, ICSR, PSURs, post approval expedited reporting, pharmacovigilance Planning, good clinical practices
This presentation gives a brief knowledge of CIOMS, its history, missions and collaborations of CIOMS. This presentation also contains CIOMS organizational structure, detailed knowledge of CIOMS Former and Present Working Groups. This will also guide about CIOMS form, its reporting and details to be filled while reporting an ADR.
An Individual Case Safety Report (ICSR) is a document that contains information about a single adverse event or suspected adverse reaction to a medicinal product. It is a critical component of pharmacovigilance, which is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems.
ICSRs are typically generated by healthcare professionals, patients, or clinical trial investigators, and they include a detailed description of the adverse event, patient demographics, medical history, and details about the medicinal product(s) involved. The report also contains an assessment of the causal relationship between the adverse event and the medicinal product(s), as well as any medical interventions or outcomes that occurred.
ICSRs are essential for identifying potential safety issues with medicinal products and for assessing the risk-benefit profile of a product. They also help to ensure that regulatory authorities, such as the FDA or EMA, are notified of any safety concerns associated with a medicinal product.
ICSRs must comply with international reporting requirements, which specify the information that must be included in the report, as well as the timeframe for submission. The information in an ICSR must be accurate and complete to enable effective analysis and evaluation of the safety data.
ICSRs are a crucial aspect of pharmacovigilance and the regulatory process, as they provide valuable information for the ongoing evaluation of the safety of medicinal products. The prompt reporting of ICSRs is essential for ensuring the timely detection and assessment of any safety concerns associated with the use of medicinal products.
Drug Safety & Pharmacovigilance - Introduction - Katalyst HLSKatalyst HLS
Introduction to Drug Safety & Pharmacovigilance in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Anatomic Therapeutic Chemical Classification, Defined daily dose, Drug utilis...Dr.Amreen Saba Attariya
detailed information about Anatomic Therapeutic Chemical Classification, Defined daily dose, Drug utilisation, DU90%, WHO Collaborting Centre for drug statistic methodology, DDD/1000inhabitants/day, DDD/100beddays, DDD/1000inhabitants/year, Pediatric DDD, ATC & DDD in drug utilisation research, Electronic Prescribing, Guidelines for ATC classification & DDD assignment 2016
Introduction to Argus Analysis Tab Screen in Pharmacovigilance or Drug Safety of Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Introduction to Argus Event Tab Screen in Pharmacovigilance or Drug Safety of Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Organization and objectives of ICH, expedited reporting, ICSR, PSURs, post approval expedited reporting, pharmacovigilance Planning, good clinical practices
This presentation gives a brief knowledge of CIOMS, its history, missions and collaborations of CIOMS. This presentation also contains CIOMS organizational structure, detailed knowledge of CIOMS Former and Present Working Groups. This will also guide about CIOMS form, its reporting and details to be filled while reporting an ADR.
An Individual Case Safety Report (ICSR) is a document that contains information about a single adverse event or suspected adverse reaction to a medicinal product. It is a critical component of pharmacovigilance, which is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems.
ICSRs are typically generated by healthcare professionals, patients, or clinical trial investigators, and they include a detailed description of the adverse event, patient demographics, medical history, and details about the medicinal product(s) involved. The report also contains an assessment of the causal relationship between the adverse event and the medicinal product(s), as well as any medical interventions or outcomes that occurred.
ICSRs are essential for identifying potential safety issues with medicinal products and for assessing the risk-benefit profile of a product. They also help to ensure that regulatory authorities, such as the FDA or EMA, are notified of any safety concerns associated with a medicinal product.
ICSRs must comply with international reporting requirements, which specify the information that must be included in the report, as well as the timeframe for submission. The information in an ICSR must be accurate and complete to enable effective analysis and evaluation of the safety data.
ICSRs are a crucial aspect of pharmacovigilance and the regulatory process, as they provide valuable information for the ongoing evaluation of the safety of medicinal products. The prompt reporting of ICSRs is essential for ensuring the timely detection and assessment of any safety concerns associated with the use of medicinal products.
Drug Safety & Pharmacovigilance - Introduction - Katalyst HLSKatalyst HLS
Introduction to Drug Safety & Pharmacovigilance in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Anatomic Therapeutic Chemical Classification, Defined daily dose, Drug utilis...Dr.Amreen Saba Attariya
detailed information about Anatomic Therapeutic Chemical Classification, Defined daily dose, Drug utilisation, DU90%, WHO Collaborting Centre for drug statistic methodology, DDD/1000inhabitants/day, DDD/100beddays, DDD/1000inhabitants/year, Pediatric DDD, ATC & DDD in drug utilisation research, Electronic Prescribing, Guidelines for ATC classification & DDD assignment 2016
Introduction to Argus Analysis Tab Screen in Pharmacovigilance or Drug Safety of Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Introduction to Argus Event Tab Screen in Pharmacovigilance or Drug Safety of Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Introduction to Expectedness/Unexpectedness Assessment in Drug Safety & Pharmacovigilance of Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Reconciliation and Literature Review and Signal Detection_Katalyst HLSKatalyst HLS
Introduction Reconciliation and Literature Review and Signal Detection in Drug Safety & Pharmacovigilance in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Introduction to ICSR Narrative Writing in Drug Safety & Pharmacovigilance in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Introduction to Argus Product Tab Screen in Pharmacovigilance or Drug Safety of Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Study setup_Clinical Data Management_Katalyst HLSKatalyst HLS
Introduction to Study Setup in Clinical Data Management in Clinical Trials of Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Introduction to Oracle Clinical Overview in Clinical Data Management in Clinical Trials of Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Introduction to Aggregate Reporting in Drug Safety & Pharmacovigilance in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Argus Patient Screen Tab Training - Katalyst HLSKatalyst HLS
Introduction to Argus Patient Screen Tab in Pharmacovigilance or Drug Safety of Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Introduction to ICSR Workflow and Management in Drug Safety & Pharmacovigilance of Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
ARGUS Query Process Overview_Katalyst HLSKatalyst HLS
Introduction to ARGUS Query Process Overview in Drug Safety & Pharmacovigilance in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Overview of Validation in Pharma_Katalyst HLSKatalyst HLS
Introduction to Validation Concepts in Pharma, Bio-Pharma, Medical Device, Cosmetics, Food, Beverages industry.
Contact:
Katalyst Healthcare’s & Life Sciences
South Plainfield, NJ, USA 07080.
E-Mail: info@KatalystHLS.com
Argus Screen Shots General Tab - Katalyst HLSKatalyst HLS
Introduction to Argus Screen Shots General Tab - Drug Safety & Pharmacovigilance of Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Pharmacovigilance Process Work Flow - Katalyst HLSKatalyst HLS
Introduction to Drug Safety & Pharmacovigilance Process Work Flow for Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Pharmacovigilance in USA and Europe_Katalyst HLSKatalyst HLS
Introduction to Drug Safety & Pharmacovigilance in USA and Europe for Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Adverse Events and Serious Adverse Events - Katalyst HLSKatalyst HLS
Introduction to Adverse Events & Serious Adverse Events in Pharmacovigilance and Drug Safety in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Presentation by David Farber, FDA Life Science Partner at King & Spalding, about US Reimbursement.
I. Introduction
• II. FDA Approval vs. Reimbursement
• a. Different Standards
b. Clinical Evidence Needed
• III. The Three Keys to Reimbursement
A. Coverage
B. Coding
C. Payment
• IV. What’s New for 2019
• V. Reimbursement for MedTech AI Solutions
• VI. Tips for Successful Reimbursement
Advancing Medical Device Interoperability (MDI)Brandon Lock
Presentation to accompany the white paper, Advancing Medical Device Interoperability: Operationalizing the Integrated Clinical Environment and Building the Environment for Medical Device Interoperability.
Student: Brandon Lock
Class: HESY 670 - Introduction to Health Information Systems
Instructor: Dr. Hon Pak
A webinar hosted by CHIME. It shared thoughts on one of my areas of interest – harnessing both business intelligence and health IT, for more effective measurement of healthcare performance.
Clinical Data Models - The Hyve - Bio IT World April 2019Kees van Bochove
Population genetics and genomics is an emerging topic for the application of machine learning methods in healthcare and biomedical sciences. Currently, several large genomics initiatives, such as Genomics England, UK Biobank, the All of Us Project, and Europe's 1 Million Genomes Initiative are all in the process of making both clinical and genomics data available from large numbers of patients to benefit biomedical research. However, a key challenge in these initiatives is the standardization of the clinical and outcomes data in such a way that machine learning methods can be effectively trained to discover useful medical and scientific insights. In this talk, we will look at what data is available at scale, and review some of examples of the application of common data and evidence models such as OMOP, FHIR, GA4GH etc. in order to achieve this, based on projects which The Hyve has executed with some of these initiatives to harmonize their clinical, genomics, imaging and wearables data and make it FAIR.
A crucial stage in clinical research is clinical data management CDM , which produces high quality, reliable, and statistically sound data from clinical trials. This results in a significantly shorter period of time between drug development and marketing. Team members of CDM are laboriously involved in all stages of clinical trials right from commencement to completion. They should be able to sustain the quality standards set by CDM processes by having sufficient process expertise. colorful procedures in CDM including Case Report Form CRF designing, CRF reflection, database designing, data entry, data confirmation, distinction operation, medical coding, data birth, and database locking are assessed for quality at regular intervals during a trial. In the present script, theres an increased demand to ameliorate the CDM norms to meet the nonsupervisory conditions and stay ahead of the competition by means of brisk commercialization of products. With the perpetration of nonsupervisory biddable data operation tools, the CDM platoon can meet these demands. also, its getting obligatory for companies to submit the data electronically. CDM professionals should meet applicable prospects and set norms for data quality and also have the drive to acclimatize to the fleetly changing technology. This composition highlights the processes involved and provides the anthology an overview of the tools and norms espoused as well as the places and liabilities in CDM. Syed Shahnawaz Quadri | Syeda Saniya Ifteqar | Syed Shafa Raoof "Data Management in Clinical Research" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-7 | Issue-2 , April 2023, URL: https://www.ijtsrd.com.com/papers/ijtsrd55050.pdf Paper URL: https://www.ijtsrd.com.com/pharmacy/other/55050/data-management-in-clinical-research/syed-shahnawaz-quadri
Have full fleged clinical trial data management systems which bring them a good amount of business and revenue.
CDM is a fundamental process which controls data accuracy of each trial besides helping the timelessness to be achieved.
It helps in linking clinical research co-ordinator = who monitor all the sites & collects the data.
it Links with biostatisticians = who analyze, interpret and report data in clinically meaningful way.
US Healthcare Reimbursement for MedTech & Digital HealthLevi Shapiro
Overview of the US healthcare reimbursement framework as it relates to MedTech and Digital Health companies by David Farber, Senior Partner, King & Spalding law firm. Includes Introduction FDA Approval vs. Reimbursement; Different Standards; Clinical Evidence Needed; The Three Keys to Reimbursement Coverage; Coding; Payment; What’s New for 2019 Reimbursement for MedTech; AI Solutions Tips for Successful Reimbursement
Analytical Wizards' Claims Data Navigator for Patient Journey and MoreEric Levin
AW uses state-of-the art big data technologies, expert analytical methodologies, and deep healthcare industry expertise to mine massive claims databases to derive targeted insights for Patient Journey Analysis, Physician Targeting, Outcome Prediction, and more.
Patient’s Journey using Real World Data and its Advanced AnalyticsKevin Lee
Real World Data (RWD) is data collected outside of clinical trial study, and Real-World Evidence (RWE) could be achieved through the insight from RWD. RWD sources come from EMR, health insurance claims, genomic data, and IoT from apps and wearables. RWD anonymized patient data has revolutionized how companies view patient data since it captures longitudinal pharmacy prescription, medical claims, and diagnosis.
The paper is written for those who want to understand how RWD patient data are collected and how they could be analyzed to support pharmaceutical companies. Mainly, RWD patient data could support patient analytics, commercial analytics, and payer analytics such as source of business, switch of prescription, payment method, market analysis, promotional activities, drug launch and forecasting. The paper also discusses the technology that data scientists use for RWD such as Data Warehouse, Data Visualization, Opensource Programming, Cloud Computing, GitHub, and Machine Learning.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
DISSERTATION on NEW DRUG DISCOVERY AND DEVELOPMENT STAGES OF DRUG DISCOVERYNEHA GUPTA
The process of drug discovery and development is a complex and multi-step endeavor aimed at bringing new pharmaceutical drugs to market. It begins with identifying and validating a biological target, such as a protein, gene, or RNA, that is associated with a disease. This step involves understanding the target's role in the disease and confirming that modulating it can have therapeutic effects. The next stage, hit identification, employs high-throughput screening (HTS) and other methods to find compounds that interact with the target. Computational techniques may also be used to identify potential hits from large compound libraries.
Following hit identification, the hits are optimized to improve their efficacy, selectivity, and pharmacokinetic properties, resulting in lead compounds. These leads undergo further refinement to enhance their potency, reduce toxicity, and improve drug-like characteristics, creating drug candidates suitable for preclinical testing. In the preclinical development phase, drug candidates are tested in vitro (in cell cultures) and in vivo (in animal models) to evaluate their safety, efficacy, pharmacokinetics, and pharmacodynamics. Toxicology studies are conducted to assess potential risks.
Before clinical trials can begin, an Investigational New Drug (IND) application must be submitted to regulatory authorities. This application includes data from preclinical studies and plans for clinical trials. Clinical development involves human trials in three phases: Phase I tests the drug's safety and dosage in a small group of healthy volunteers, Phase II assesses the drug's efficacy and side effects in a larger group of patients with the target disease, and Phase III confirms the drug's efficacy and monitors adverse reactions in a large population, often compared to existing treatments.
After successful clinical trials, a New Drug Application (NDA) is submitted to regulatory authorities for approval, including all data from preclinical and clinical studies, as well as proposed labeling and manufacturing information. Regulatory authorities then review the NDA to ensure the drug is safe, effective, and of high quality, potentially requiring additional studies. Finally, after a drug is approved and marketed, it undergoes post-marketing surveillance, which includes continuous monitoring for long-term safety and effectiveness, pharmacovigilance, and reporting of any adverse effects.
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
2. MedDRA was developed under the auspices of the
International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for
Human Use (ICH). The activities of the MedDRA
Maintenance and Support Services Organization (MSSO)
are overseen by an ICH MedDRA Management Board,
which is composed of the six ICH parties (EU, EFPIA,
MHLW, JPMA, FDA, PhRMA), the Medicines and Healthcare
products Regulatory Agency (MHRA) of the UK, Health
Canada, and the WHO (as Observer).
2MSSO-DI-6225-19.0.0
3. Disclaimer and
Copyright Notice
This presentation is protected by copyright and may be used, reproduced,
incorporated into other works, adapted, modified, translated or distributed under a
public license provided that ICH's copyright in the presentation is acknowledged at
all times. In case of any adaption, modification or translation of the presentation,
reasonable steps must be taken to clearly label, demarcate or otherwise identify
that changes were made to or based on the original presentation. Any impression
that the adaption, modification or translation of the original presentation is
endorsed or sponsored by the ICH must be avoided.
The presentation is provided "as is" without warranty of any kind. In no event shall
the ICH or the authors of the original presentation be liable for any claim, damages
or other liability arising from the use of the presentation.
The above-mentioned permissions do not apply to content supplied by third parties.
Therefore, for documents where the copyright vests in a third party, permission for
reproduction must be obtained from this copyright holder.
MSSO-DI-6225-19.0.0 3
4. Overview
To provide an understanding of:
• Importance of good quality data
• How clinical data are coded
• MedDRA background
• Coding examples
• Benefits of good quality data
MSSO-DI-6225-19.0.0 4
5. Data Quality in Clinical
Development
• Highly regulated environment with strong
emphasis on safety surveillance and data
quality
• Applies to clinical trials and post-marketing
arena
• Increasing harmonization of safety reporting
regulations globally
MSSO-DI-6225-19.0.0 5
6. What is Meant by
Good Quality Data?
• Complete
• Accurate
• Diagnosis supported by appropriate
investigations
• Causality assessment for adverse events
MSSO-DI-6225-19.0.0 6
7. Quality of Input = Quality
of Output
IN OUT
MSSO-DI-6225-19.0.0 7
8. Coding of Clinical Trial
Data
• Most data entered on Case Report Forms are “coded” in
some form
• Facilitates storage, retrieval, analysis, and presentation of
data
• Some coding is performed by investigators at point of data
entry
– For example, numeric codes for severity of adverse event: 1= mild,
2= moderate, etc.
• Other coding of text data is performed by the sponsor
company after data collection
• Accuracy of initial coding determines accuracy of analysis
MSSO-DI-6225-19.0.0 8
10. What is MedDRA?
Med = Medical
D = Dictionary for
R = Regulatory
A = Activities
MSSO-DI-6225-19.0.0 10
11. MedDRA Definition
MedDRA is a clinically-validated international
medical terminology used by regulatory
authorities and the regulated
biopharmaceutical industry. The terminology
is used through the entire regulatory
process, from pre-marketing to post-
marketing, and for data entry, retrieval,
evaluation, and presentation.
MSSO-DI-6225-19.0.0 11
12. Where MedDRA is Used
Individual Case Safety Reports and Safety Summaries
Clinical Study Reports
Investigators’ Brochures
Core Company Safety Information
Marketing Applications
Publications
Prescribing Information
Advertising
Regulatory Authority and Industry Databases
MSSO-DI-6225-19.0.0 12
13. Key Features of MedDRA
• Standardized terminology
• International scope – currently available in
11 languages including English, Spanish,
French, Chinese, and Japanese
• Managed by Maintenance and Support
Services Organization (MSSO) and updated
bi-annually with input from users
MSSO-DI-6225-19.0.0 13
14. Key Features of MedDRA
(cont)
• Structure facilitates data entry, analysis, reporting,
and electronic communication
• Large terminology with > 75,000 terms at lowest
level - allows greater specificity
• Approx. 22,000 Preferred Terms, each representing
a unique medical concept
• Used to classify a wide range of information
associated with the use of biopharmaceuticals and
other medical products (e.g., medical devices and
vaccines).
MSSO-DI-6225-19.0.0 14
15. Scope of MedDRA
Medical conditions
Indications
Investigations (tests, results)
Medical and surgical procedures
Medical, social, family history
Medication errors
Product quality issues
Device-related issues
Pharmacogenetic terms
Toxicologic issues
Standardized queries
Not a drug
dictionary
Not an equipment, device,
diagnostic product dictionary
Clinical trial study
design terms
Patient demographic
terms
Frequency
qualifiers
Numerical values for
results
Severity descriptors
IN
OUT
MSSO-DI-6225-19.0.0 15
16. Regulatory Status
• US FDA
– Used in several databases including FAERS (drugs and
biologics), VAERS (vaccines), and CAERS (foods, dietary
supplements, cosmetics)
– Recommended terminology for adverse event reporting
in several Proposed Rules and Guidances
– Effective June 2015, electronic submission required for
postmarketing safety reports for drugs, biologics, and
vaccines (relies upon ICH standards)
• Japanese Ministry of Health, Labour and Welfare
– Mandatory use in electronic reporting
MSSO-DI-6225-19.0.0 16
17. Regulatory Status (cont)
• European Union
– EudraVigilance database
• Clinical trial SUSARs (Suspected Unexpected Serious Adverse
Reactions)
• Post-authorization Individual Case Safety Reports (ICSRs)
• Requires current version of MedDRA or the one previous to it
– Good pharmacovigilance practices (GVP) specifically
mention MedDRA
– Pharmacovigilance legislation covers suspected adverse
reactions from:
• Use inside and outside terms of marketing authorization
• Overdose, misuse, abuse, and medication errors
• Occupational exposures
MSSO-DI-6225-19.0.0 17
18. Regulatory Status (cont)
• European Union (cont)
– Used in interface between EudraVigilance and EU Risk
Management Plan
– Used throughout Summary of Product Characteristics
(labeling)
• ICH M4E Guideline on Common Technical Document
– Recommended in adverse event summary tables
• Canada
– Used in Canada Vigilance database
– Recommended/preferred terminology for adverse reaction
reporting and Product Monograph (labeling)
– Electronic reporting via Gateway requires current version of
MedDRA
MSSO-DI-6225-19.0.0 18
19. Making the Most of
MedDRA
• To take advantage of MedDRA’s richness and
specificity, the source data should be
– Clear
– Concise
– Complete
– Accurate
• General principles apply to all clinical data
MSSO-DI-6225-19.0.0 19
20. Problems With Coding
Data
• Appropriate coding requires clear initial data
• What is clear to the investigator at the point of data
entry may be unclear to the sponsor at the point of
data coding
• Sponsor must only code reported verbatim term; not
permitted to interpret or draw information from other
sources
• Example: Ambiguous information
– Congestion (nasal, liver, sinus, pulmonary?)
– Cramp (muscle, menstrual, abdominal?)
– Pain (pain where?)
MSSO-DI-6225-19.0.0 20
21. Problems With Coding
Data (cont)
• Example: Ambiguous abbreviations
– MI (myocardial infarction or mitral incompetence?)
– GU pain (gastric ulcer pain or genito-urinary pain?)
– Decreased BS (breath sounds, bowel sounds or blood
sugar?)
• Exercise caution with abbreviations that could be
misinterpreted
• ECG, COPD, HIV are examples of standard
abbreviations
MSSO-DI-6225-19.0.0 21
22. Problems With Coding
Data (cont)
• Example: Vague information
– Patient felt “fuzzy”, “weird”, “experienced every adverse
event”
Try to use accepted medical terminology
• Example: Non-specific information
– “Left wrist edema” (coded as Peripheral edema)
– More specific - “Injection site edema left wrist” (coded as
Injection site edema)
MSSO-DI-6225-19.0.0 22
23. Problems With Coding
Data (cont)
• Death, hospitalization, and disability are outcomes
and are not usually considered to be adverse
events
• Provide details of the underlying event, if known
• Examples:
– “Death due to myocardial infarction” (Coded as
Myocardial infarction with death captured as the
outcome)
– “Hospitalization due to congestive heart failure” (Coded
as Congestive heart failure with hospitalization captured
as the outcome)
MSSO-DI-6225-19.0.0 23
24. Problems With Coding
Data (cont)
• Example: Ambiguous laboratory data
– “Glucose of 40”
– (Source of specimen - blood, urine, CSF? What units?)
– Would have to code as Glucose abnormal if additional
clarification is not obtained
• Example: Conflicting laboratory data
– “Hyperkalemia with serum potassium of 1.6 mEq/L”
– Would have to code as Serum potassium abnormal
If using numeric values, provide units and
reference range. Be specific about specimen source
and diagnostic result/clinical diagnosis.
MSSO-DI-6225-19.0.0 24
25. Problems With Coding
Data (cont)
• Example: Combination terms
– Diarrhea, nausea, and vomiting
Try to avoid combination terms - these will
have to be split into three individual terms
Diarrhea
Nausea
Vomiting
MSSO-DI-6225-19.0.0 25
26. Reporting a Specific
Diagnosis
• Where possible, report the most important medical
event or specific diagnosis rather than individual
signs and symptoms
• Can provide provisional diagnosis e.g. “possible”,
“presumed”, “rule out”
• Accuracy is important in preventing dilution of
safety signals or generating false signals
SIGNS and SYMPTOMS DIAGNOSIS
Chest pain, dyspnea,
diaphoresis, ECG changes
Myocardial infarction
MSSO-DI-6225-19.0.0 26
27. Safety Signals
• Accuracy in diagnosis is important for detection and
evaluation of safety signals
• Events of importance in drug safety surveillance
include:
– QTc prolongation
– Hepatotoxicity
– Stevens Johnson syndrome
– Convulsions
– Rhabdomyolysis
MSSO-DI-6225-19.0.0 27
28. Generating Quality Data
• Clear
• Concise
• Complete
• Accurate
• Be specific if necessary - MedDRA can handle
multiple specific medical concepts:
– Headache - more than 50 types, including cluster, sinus,
migraine, lumbar puncture headache
– Organisms - down to species level e.g. Staphylococcus
aureus
MSSO-DI-6225-19.0.0 28
29. Quality Assurance
• Human oversight of automated coding
results
– Example: “Allergic to CAT scan” autoencoded as:
Allergic to cats
• Qualification of coder/review staff
• Errors in MedDRA should be addressed by
submission of Change Requests to MSSO; no
ad hoc structural alterations to MedDRA
MSSO-DI-6225-19.0.0 29
30. FDA-Defined Coding
Errors
• Missed Concepts
– All medical concepts described after the product is taken
should be coded
– Example: “The patient took drug X and developed
alopecia, increased LFTs and pancreatitis”. Manufacturer
only codes alopecia and increased LFTs (missed concept
of pancreatitis)
– Example: “The patient took drug X and developed
interstitial nephritis which later deteriorated into renal
failure”. Manufacturer only codes interstitial nephritis
(missed renal failure concept)
Acknowledgement: Dr. Toni Piazza-Hepp, Office of Surveillance
and Epidemiology, CDER
MSSO-DI-6225-19.0.0 30
31. FDA-Defined Coding
Errors (cont)
• “Soft Coding”
– Selecting a term which is both less specific and less
severe than another MedDRA term is “soft coding”
– Example: “Liver failure” coded as hepatotoxicity or
increased LFTs
– Example: “Aplastic anemia” coded as unspecified anemia
– Example: “Rash subsequently diagnosed as Stevens
Johnson syndrome” coded as rash
Acknowledgement: Dr. Toni Piazza-Hepp, Office of Surveillance
and Epidemiology, CDER
MSSO-DI-6225-19.0.0 31
32. Miscellaneous Verbatims:
Coding Challenges
– Went to hell
– Recurrent fatal stroke
– Hears New Age music when the furnace turns on
– LK RTCTL UNSP XTRNDL
– Charcoal-like, gritty granules in his underwear
– Can’t control patient during menses
– His nodule is sticking out
– Normally normal after drinking coffee
– Died of cancer of the placebo
– Superior members fornication
– Barely visible posterior
– Seeing people in room, seeing chickens at window
– Seeing stars and chicken farting
– Patient recently began new job where he works around chicken wings and
barbecue sauce
MSSO-DI-6225-19.0.0 32
33. Company-specific
conventions
• Insert slides as required to cover company’s specific
data collection and recording conventions
• Could include instructions on how to complete data
fields for adverse events, medical history etc. on
paper or electronic CRFs
• Could include general principles of how to record
text-based information as well as specific
instructions for particular therapeutic areas
MSSO-DI-6225-19.0.0 33
34. Benefits of Quality Data
• Accurate and timely information on issues that
affect conduct of clinical trial and affect patient
safety
• Improved communication among sponsors,
investigators, and regulatory agencies about
medicinal products
– Aids in safety signal detection and evaluation
– Ensures accuracy of information about the product
including investigators’ brochures and prescribing
information
– Benefits medical professionals
– Benefits patients
MSSO-DI-6225-19.0.0 34
35. Benefits of Quality Data
(cont)
• Fewer queries for investigator and sponsor
MSSO-DI-6225-19.0.0 35